The Research Group in "Dendrimers for Biomedical Applications" of the University of Alcalá presents a new invention that refers to the formation of nanoconjugates with antitumor activity, mainly against advanced prostate cancer. Nanoconjugates are composed of dendritic systems (dendrimers and dendrons) and neuropeptides. The dendritic molecules are mainly of carbosilane structure and with ammonium functions in the periphery. And the peptides are preferably of the glucagon / secretin family (VIP, GHRH, PACAP…etc.)
The research group seeks companies from the Biomedicine, Pharmaceutical and Health sector, to establish licensing agreements, cooperation agreements or commercial agreements with technical assistance.
The present invention provides the preparation of active nanoconjugates against advanced prostate cancer and to prevent metastasis.
The formation of the nanoconjugates is carried out by mixing in solution, preferably aqueous in the presence or absence of buffer, the dendritic molecules and the corresponding peptides, in the proportion of interest.
These systems are formed by dendritic molecules (dendrimers and dendrons) and neuropeptides. Preferably, the dendritic macromolecules are of carbosilane structure, mainly with cationic functions in the periphery, and the neuropeptides are of the glucagon / secretin family, mainly VIP, GHRH and PACAP. These nanoconjugates are formed by combining the dendritic molecule and the corresponding peptide in the necessary proportion.
The present invention also relates to the biomedical uses of the peptide / dendritic molecule combinations.
Preferably this invention is for the development of drugs for the treatment of prostate cancer. However, other types of cancers are not excluded. Examples of pharmaceutical preparations include any solid composition (tablets, pills, capsules, granules, etc.) or liquid (gels, solutions, suspensions or emulsions) for oral, nasal, topical or parenteral administration.
Current development status
Experimental technologies
Applications
Preferably this invention is for the development of drugs for the treatment of prostate cancer. However, other types of cancers are not excluded. Examples of pharmaceutical preparations include any solid composition (tablets, pills, capsules, granules, etc.) or liquid (gels, solutions, suspensions or emulsions) for oral, nasal, topical or parenteral administration.
Desired business relationship
Technology selling
Patent licensing
Technology development
The research group seeks for companies from the Biomedicine, Pharmaceutical and Health sector, to establish licensing agreements, cooperation agreements or commercial agreements with technical assistance.
The Technology Transfer Office at Alcalá University serves as a liaison between the University and its socioeconomic environment in terms of research and innovation. It encorages collaboration between research groups from universities and companies/institutions, with the objective to promote and commercialize research results and scientific capabilities.
Some of the services offered by this office are specified in the following list:
- Promotion of R & D and improvement of the relationships with companies.
- Promote the participation in R & D projects applicants to public calls (regional, national and European).
- Advising, processing and monitoring of patents and other forms of industrial protection.
- Support in the negotiation of contracts and agreements for R&D&i
Create your free account to connect with Universidad de Alcalá-OTRI and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Universidad de Alcalá-OTRI
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
